Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04505878
Other study ID # 2020-0503
Secondary ID A530900SMPH/ANES
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date April 2023
Est. completion date December 2023

Study information

Verified date April 2023
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being done to determine if parenterally administered ascorbic acid (Vitamin C) given at the time of lung transplant is safe. Vitamin C may be an effective intervention towards primary graft dysfunction (PGD). The study will enroll 69 participants who consent to the intervention. Participants who do not consent to the intervention will be treated according to standard-of-care, but may choose to be consented to have their data retrospectively reviewed. Based on our consent rate, this group may include 40-70 participants. Participants will be on study for up to 12 months.


Description:

PGD is a frequent and severe outcome that impacts both short- and long-term outcomes after lung transplantation. Major pathophysiologic contributors include ischemia and reperfusion injury, mitochondrial dysfunction and endothelial failure. No directed therapy exists. Vitamin C is a first-line antioxidant that also acts at the endothelium and mitochondria to decrease permeability and leak, inhibit mitochondrial dysfunction and improve ischemia and reperfusion. When combined with steroids, part of standard care for lung transplant recipients, these effects may be enhanced and synergistically inhibit instigators of patient injury. A pilot trial will ensure safety of this potential intervention and guide future research into this important outcome measure. It will be readily received in the literature. For the present study, vitamin C will be administered parenterally at a dose of 1,500 mg every 6 hours, a dose that is widely accepted and used in other clinical contexts where the drug is studied, such as sepsis. This will predictably reconstitute levels and achieve supratherapeutic benefit towards oxidant scavenging, while avoiding the potential pro-oxidant effects seen at exceedingly high doses. To this end, the investigators will exclude patients where the standard dosing of vitamin C will exceed 100 mg/kg/day (excluding patients <60 kg). Dosing will continue through post-operative day (POD) 3 to effectively assess for the impact of vitamin C on PGD. Primary Objectives - To assess whether parenterally administered ascorbic acid (vitamin C) is safe in the lung transplant population - To estimate adherence to ascorbic acid administration protocol in this study population and to identify obstacles to feasibility of future trials using this protocol Secondary Objectives - To assess whether parenterally administered ascorbic acid (vitamin C) may decrease the rate and severity of PGD after lung transplant - To establish the incidence of vitamin C and vitamin B1 (thiamine) deficiencies in the lung transplant population, and the responsiveness of vitamin C levels to our selected parenteral therapy - To identify interventions that will optimize the post-operative wellbeing of patients receiving lung transplants by decreasing primary graft dysfunction (short and intermediate-to-long term Stop Criteria - Anuria x 3-hours - Moderate, Grade 2 AKI (doubling of baseline creatinine) - An acute, unexplained hemoglobin drop of >2 mg/dL


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Participant is scheduled for lung transplantation Exclusion Criteria: - Non-English speaking - Subject is known or believed to be pregnant - Subject is a prisoner. - Subject has impaired decision-making capacity. - Subject has known allergy to vitamin C. - Subject has history of nephrolithiasis, oxalosis or hyperoxaluria. (Cystic Fibrosis patients are at risk of occult oxalosis / hyperoxaluria, therefore they will also be excluded from the study.) - Glucose-6-phosphate dehydrogenase (G6PD) deficiency - Sickle cell anemia - Heredity hemochromatosis - Baseline creatinine >2 mg/dL or any current kidney injury - Weight <60 kg - Vitamin C supplement use or administration (including HAT therapy) within the last month prior to transplantation - Current enrolment in another research study - Not suitable for study participation due to other reasons at the discretion of the investigators.

Study Design


Intervention

Drug:
Vitamin C
Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and Severity of Kidney Injury Post Operative Day (POD) 1 The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis). Post Operative Day 1
Primary Incidence and Severity of Kidney Injury POD 2 The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis). Post Operative Day 2
Primary Incidence and Severity of Kidney Injury POD 3 The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis). Post Operative Day 3
Primary Incidence and Severity of Kidney Injury POD 4 The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis). Post Operative Day 4
Primary Incidence and Severity of Kidney Injury POD 7 The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis). Post Operative Day 7
Primary Incidence of New Dialysis Initiation up to Post Operative Day 7
Secondary Participant Vitamin C Levels Baseline, Post Operative Day 1, Post Operative Day 2, Post Operative Day 3
Secondary Participant Thiamine Levels Baseline, Post Operative Day 1, Post Operative Day 2, Post Operative Day 3
Secondary Incidence of Primary Graft Dysfunction (PGD) Primary Graft Dysfunction is defined as chest x-ray (CXR)-infiltrates with or without depressed oxygenation function, assessed by the "PF-Ratio," which is the PaO2 / FiO2. up to Post Operative Day 7
Secondary Incidence and Severity of PGD on POD 3 Primary Graft Dysfunction is defined as chest x-ray (CXR)-infiltrates with or without depressed oxygenation function, assessed by the "PF-Ratio," which is the PaO2 / FiO2. Severity is defined as: PGD Grade 1 = CXR findings and any PF Ratio > 300; PGD Grade 2 = CXR findings and PF Ratio 200-300; and PGD Grade 3 = CXR findings and PF Ratio <200. Post Operative Day 3
Secondary Tacrolimus Levels Post Operative Days 2, 3, 4, and 7
Secondary Tacrolimus Doses Post Operative Days 4 and 7
Secondary Post-Operative Well Being: Mortality at Post Operative Day 30 and Post Operative Day 90 via chart review
Secondary Post-Operative Well Being: Atrial Fibrillation up to Post Operative Day 7
Secondary Post-Operative Well Being: ICU Length of Stay up to Post Operative Day 30 (chart review)
Secondary Post-Operative Well Being: Hospital Length of Stay up to Post Operative Day 90 (chart review)
Secondary Post-Operative Well Being: Nadir Cardiac Index up to 72 hours post op
Secondary Post-Operative Well Being: Peak Pulmonary Artery Systolic Pressure up to 72 hours post op
Secondary Post-Operative Well Being: Peak Pulmonary Artery Diastolic Pressure up to 72 hours post op
Secondary Post-Operative Well Being: Duration of Inotrope Need up to 72 hours post op
Secondary Post-Operative Well Being: Duration of Vasopressor up to 72 hours post op
Secondary Post-Operative Well Being: Total Dose of Vasopressor up to 72 hours post op
Secondary Post-Operative Well Being: Daily Crystalloid Volume for 0-24h, 24-48h and 48-72h; total volume balance at 72-hours up to 72 hours post op
Secondary Post-Operative Well Being: Daily Blood Product Transfusion Volume for 0-24h, 24-48h and 48-72h; total volume balance at 72-hours up to 72 hours post op
Secondary Post-Operative Well Being: Daily Chest Tube Output Volume for 0-24h, 24-48h and 48-72h; total volume balance at 72-hours up to 72 hours post op
Secondary Post-Operative Well Being: Duration of Post-Operative Mechanical Ventilation up to Post Operative Day 7
Secondary Post-Operative Well Being: PaO2 / FIO2 ratios The PF Ratio assesses the lungs' ability to oxygenate the blood. It is defined as the ratio of the partial pressure of oxygen in the arteries (PaO2 in mmHg) to the fractional inspired oxygen content from the ventilator (FiO2 in %). Post Operative Day 1, Post Operative Day 2, Post Operative Day 3
Secondary Post-Operative Well Being: Time to Clearance of Lactate "Clearance" is defined as a lactate <1 mmol/L. up to Post Operative Day 3
See also
  Status Clinical Trial Phase
Recruiting NCT05526950 - Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb) N/A
Recruiting NCT05916495 - An Evaluation of Remote Care (Questionnaire+Hybrid) in Patients Who Are Post-lung Transplant N/A
Enrolling by invitation NCT05950724 - RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant Early Phase 1
Active, not recruiting NCT05505422 - Routine Versus Selective Intraoperative ECMO in Lung Transplant N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Enrolling by invitation NCT04522388 - Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant N/A
Completed NCT04165161 - Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography N/A
Recruiting NCT05050955 - AlloSure Lung Assessment and Metagenomics Outcomes Study
Withdrawn NCT03258801 - Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
Completed NCT04892719 - 4DX Functional Lung Imaging in the Diagnosis of Chronic Lung Allograft Dysfunction After Lung Transplantation N/A
Completed NCT03221764 - Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients Phase 2
Active, not recruiting NCT04975607 - Live Music Therapy to Reduce Anxiety, Pain and Improve Sleep in Post-Operative Lung Transplant Patients: A Pilot Study N/A
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT03367221 - Physiological Response in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist N/A
Recruiting NCT03276403 - Primary Graft Dysfunction Score in Lung Transplantation N/A
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT05242289 - Cytokine Adsorption in Lung Transplantation N/A
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Not yet recruiting NCT04377139 - Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)
Not yet recruiting NCT06399302 - Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes